English
简体中文
Total: £ 56.28
Published Date: 2026-04-07 | Pages: 107 | Tables: 101 | Medical Care
The global Pharmacogenomics Technology (Theranostics & CDx) market was valued at US$ 14260 million in 2025 and is anticipated to reach US$ 36770 million by 2032, at a CAGR of 14.7% from 2026 to 2032.
Pharmacogenomics Technology (Theranostics & CDx) manufacturers include Illumina, Roche and Agilent etc. The top 3 company holds a share of more than 50%. North America takes up the largest sales market, with a share of more than 40%, followed by Europe and China, with the share of about 30% and 10% respectively.
This report delivers a comprehensive overview of the global Pharmacogenomics Technology (Theranostics & CDx) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pharmacogenomics Technology (Theranostics & CDx). The Pharmacogenomics Technology (Theranostics & CDx) market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Pharmacogenomics Technology (Theranostics & CDx) market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Pharmacogenomics Technology (Theranostics & CDx) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Illumina
Roche
Agilent
Abbott
Thermofisher
Qiagen
Guardant Health
MGI Tech Co., Ltd.
Amoydx Biology
Genomics
Segment by Type
Instrument
Reagents and Consumables
Others
Segment by Application
Tumor
Diabetes
Mental Diseases
Cardiovascular Diseases
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Pharmacogenomics Technology (Theranostics & CDx) companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Instrument
1.2.3 Reagents and Consumables
1.2.4 Others
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Mental Diseases
1.3.5 Cardiovascular Diseases
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2021–2032)
2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
2.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2021–2026)
2.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2027–2032)
2.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
2.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
2.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
2.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
2.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue
3.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2021–2026)
3.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2021–2026)
3.2 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Pharmacogenomics Technology (Theranostics & CDx) Revenue
3.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2025
3.5 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx) Head Offices and Areas Served
3.6 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Products and Applications
3.7 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Type
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2021–2026)
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2027–2032)
5 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Application
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2021–2026)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021–2032)
6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021–2026)
6.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021–2032)
7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021–2026)
7.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021–2032)
8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021–2026)
8.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021–2032)
9.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021–2026)
9.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021–2032)
10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021–2026)
10.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Details
11.1.2 Illumina Business Overview
11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.1.5 Illumina Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.2.5 Roche Recent Development
11.3 Agilent
11.3.1 Agilent Company Details
11.3.2 Agilent Business Overview
11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.3.5 Agilent Recent Development
11.4 Abbott
11.4.1 Abbott Company Details
11.4.2 Abbott Business Overview
11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.4.5 Abbott Recent Development
11.5 Thermofisher
11.5.1 Thermofisher Company Details
11.5.2 Thermofisher Business Overview
11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.5.5 Thermofisher Recent Development
11.6 Qiagen
11.6.1 Qiagen Company Details
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.6.5 Qiagen Recent Development
11.7 Guardant Health
11.7.1 Guardant Health Company Details
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.7.5 Guardant Health Recent Development
11.8 MGI Tech Co., Ltd.
11.8.1 MGI Tech Co., Ltd. Company Details
11.8.2 MGI Tech Co., Ltd. Business Overview
11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.8.5 MGI Tech Co., Ltd. Recent Development
11.9 Amoydx Biology
11.9.1 Amoydx Biology Company Details
11.9.2 Amoydx Biology Business Overview
11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.9.5 Amoydx Biology Recent Development
11.10 Genomics
11.10.1 Genomics Company Details
11.10.2 Genomics Business Overview
11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
11.10.5 Genomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Instrument
Table 3. Key Players of Reagents and Consumables
Table 4. Key Players of Others
Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million), 2021–2026
Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2021–2026)
Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2027–2032)
Table 11. Pharmacogenomics Technology (Theranostics & CDx) Market Trends
Table 12. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
Table 13. Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
Table 14. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (US$ Million), 2021–2026
Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Players (2021–2026)
Table 17. Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Tier (Tier 1, Tier 2, and Tier 3), based on Pharmacogenomics Technology (Theranostics & CDx) Revenue, 2025
Table 18. Ranking of Global Top Pharmacogenomics Technology (Theranostics & CDx) Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by Pharmacogenomics Technology (Theranostics & CDx) Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Headquarters and Area Served
Table 21. Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Products and Applications
Table 22. Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (US$ Million), 2021–2026
Table 25. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2021–2026)
Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2027–2032)
Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (US$ Million), 2021–2026
Table 29. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2021–2026)
Table 30. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2027–2032)
Table 32. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2021–2026
Table 34. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2027–2032
Table 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2021–2026
Table 37. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (US$ Million), 2027–2032
Table 47. Illumina Company Details
Table 48. Illumina Business Overview
Table 49. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product
Table 50. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 51. Illumina Recent Development
Table 52. Roche Company Details
Table 53. Roche Business Overview
Table 54. Roche Pharmacogenomics Technology (Theranostics & CDx) Product
Table 55. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 56. Roche Recent Development
Table 57. Agilent Company Details
Table 58. Agilent Business Overview
Table 59. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product
Table 60. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 61. Agilent Recent Development
Table 62. Abbott Company Details
Table 63. Abbott Business Overview
Table 64. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product
Table 65. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 66. Abbott Recent Development
Table 67. Thermofisher Company Details
Table 68. Thermofisher Business Overview
Table 69. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product
Table 70. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 71. Thermofisher Recent Development
Table 72. Qiagen Company Details
Table 73. Qiagen Business Overview
Table 74. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product
Table 75. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 76. Qiagen Recent Development
Table 77. Guardant Health Company Details
Table 78. Guardant Health Business Overview
Table 79. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product
Table 80. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 81. Guardant Health Recent Development
Table 82. MGI Tech Co., Ltd. Company Details
Table 83. MGI Tech Co., Ltd. Business Overview
Table 84. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product
Table 85. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 86. MGI Tech Co., Ltd. Recent Development
Table 87. Amoydx Biology Company Details
Table 88. Amoydx Biology Business Overview
Table 89. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product
Table 90. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 91. Amoydx Biology Recent Development
Table 92. Genomics Company Details
Table 93. Genomics Business Overview
Table 94. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product
Table 95. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (US$ Million), 2021–2026
Table 96. Genomics Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
Table 100. Authors List of This Report
List of Figures
Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Picture
Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type: 2025 vs 2032
Figure 4. Instrument Features
Figure 5. Reagents and Consumables Features
Figure 6. Others Features
Figure 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (US$ Million), 2021–2032
Figure 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application: 2025 vs 2032
Figure 9. Tumor Case Studies
Figure 10. Diabetes Case Studies
Figure 11. Mental Diseases Case Studies
Figure 12. Cardiovascular Diseases Case Studies
Figure 13. Others Case Studies
Figure 14. Pharmacogenomics Technology (Theranostics & CDx) Report Years Considered
Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2025 vs 2032
Figure 18. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Players in 2025
Figure 19. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2025
Figure 21. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021–2032)
Figure 23. United States Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021–2032)
Figure 27. Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2021–2032)
Figure 35. China Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021–2032)
Figure 43. Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2021–2032)
Figure 47. Israel Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Illumina Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 51. Roche Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 52. Agilent Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 53. Abbott Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 54. Thermofisher Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 55. Qiagen Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 56. Guardant Health Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 57. MGI Tech Co., Ltd. Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 58. Amoydx Biology Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 59. Genomics Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2021–2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
